Publications of Dr. Heidi Noels over the last 5 years:

 

Noels, Heidi - Search Results - PubMed (nih.gov)

  1. Noels H, Jankowski V, Schunk SJ, Vanholder R, Kalim S and Jankowski J. Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat Rev Nephrol. 2024.
     
  2. Harlacher E, Schulte C, Vondenhoff S, Schmitt-Kopplin P, Diederich P, Hemmers C, Moellmann J, Wollenhaupt J, Veltrop R, Biessen E, Lehrke M, Peters B, Schlieper G, Kuppe C, Floege J, Jankowski V, Marx N, Jankowski J and Noels H. Increased levels of a mycophenolic acid metabolite in patients with kidney failure negatively affect cardiomyocyte health. Front Cardiovasc Med. 2024;11:1346475.
     
  3. Vondenhoff S, Schunk SJ and Noels H. Increased cardiovascular risk in patients with chronic kidney disease. Herz. 2024;49:95-104.
     
  4. Moellmann J, Krueger K, Wong DWL, Klinkhammer BM, Buhl EM, Dehairs J, Swinnen JV, Noels H, Jankowski J, Lebherz C, Boor P, Marx N and Lehrke M. 2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function. Biochim Biophys Acta Mol Basis Dis. 2024;1870:166825.
     
  5. Stamellou E, Noels H and Floege J. Factor XI inhibition in hemodialysis patients: the safer anticoagulation? Kidney Int. 2024;106:21-23.
     
  6. Lellig M, Rodriguez M, Lopez-Baltanas R, Hermann J, Wollenhaupt J, Noels H, Zidek W, Tepel M, Mahfoud F, Jankowski J, Munoz-Castaneda JR and Jankowski V. Pyridoxal-5'-phosphate: A cost-effective treatment candidate for hypertensive patients? J Intern Med. 2024;296:435-448.
     
  7. Dai Y, Junho CVC, Schieren L, Wollenhaupt J, Sluimer JC, van der Vorst EPC and Noels H. Cellular metabolism changes in atherosclerosis and the impact of comorbidities. Front Cell Dev Biol. 2024;12:1446964.
     
  8. Asare Y, Simsekyilmaz S, Kohncke J, Shagdarsuren G, Staudt M, Noels H, Klos A, Fischer JC, Bernhagen J, Zernecke A, Liehn EA and Shagdarsuren E. Cardiac Repair after Myocardial Infarction is Controlled by a Complement C5a Receptor 1-Driven Signaling Cascade. Thromb Haemost. 2024.

  1. Moellmann J, Krueger K, Wong DWL, Klinkhammer BM, Buhl EM, Dehairs J, Swinnen JV, Noels H, Jankowski J, Lebherz C, Boor P, Marx N and Lehrke M. 2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function. Biochim Biophys Acta Mol Basis Dis. 2023;1870:166825.

  2. Soppert J, Heussen NM and Noels H. The authors reply. Kidney Int. 2023;103:1199-1201.

  3. Noels H and Jankowski J. Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: Introduction to a Compendium. Circ Res. 2023;132:899-901.
     
  4. Baaten C, Vondenhoff S and Noels H. Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease. Circ Res. 2023;132:970-992.
     
  5. Thakur M, Junho CVC, Bernhard SM, Schindewolf M, Noels H and Doring Y. NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease. Circ Res. 2023;132:933-949.
     
  6. Krammer C, Yang B, Reichl S, Besson-Girard S, Ji H, Bolini V, Schulte C, Noels H, Schlepckow K, Jocher G, Werner G, Willem M, El Bounkari O, Kapurniotu A, Gokce O, Weber C, Mohanta S and Bernhagen J. Pathways linking aging and atheroprotection in Mif-deficient atherosclerotic mice. FASEB J. 2023;37:e22752.
     
  7. van Kuijk K, McCracken IR, Tillie R, Asselberghs SEJ, Kheder DA, Muitjens S, Jin H, Taylor RS, Wichers Schreur R, Kuppe C, Dobie R, Ramachandran P, Gijbels MJ, Temmerman L, Kirkwoord PM, Luyten J, Li Y, Noels H, Goossens P, Wilson-Kanamori JR, Schurgers LJ, Shen YH, Mees BME, Biessen EAL, Henderson NC, Kramann R, Baker AH and Sluimer JC. Human and murine fibroblast single-cell transcriptomics reveals fibroblast clusters are differentially affected by ageing and serum cholesterol. Cardiovasc Res. 2023;119:1509-1523.
     
  8. Soppert J, Brandt EF, Heussen NM, Barzakova E, Blank LM, Kuepfer L, Hornef MW, Trebicka J, Jankowski J, Berres ML and Noels H. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21:2746-2758.
  1. Wollenhaupt J, Frisch J, Harlacher E, Wong DWL, Jin H, Schulte C, Vondenhoff S, Moellmann J, Klinkhammer BM, Zhang L, Baleanu-Curaj A, Liehn EA, Speer T, Kazakov A, Werner C, van der Vorst EPC, Selejan SR, Hohl M, Bohm M, Kramann R, Biessen EAL, Lehrke M, Marx N, Jankowski J, Maack C, Boor P, Prates Roma L and Noels H. Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease. Redox Biol. 2022;56:102459.
     
  2. Soppert J, Frisch J, Wirth J, Hemmers C, Boor P, Kramann R, Vondenhoff S, Moellmann J, Lehrke M, Hohl M, van der Vorst EPC, Werner C, Speer T, Maack C, Marx N, Jankowski J, Roma LP and Noels H. A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int. 2022;101:256-273.
     
  3. Soppert J, Brandt EF, Heussen NM, Barzakova E, Blank LM, Kuepfer L, Hornef MW, Trebicka J, Jankowski J, Berres ML and Noels H. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022.
     
  4. Hemmers C, Schulte C, Wollenhaupt J, Wong DWL, Harlacher E, Orth-Alampour S, Klinkhammer BM, Schirmer SH, Bohm M, Marx N, Speer T, Boor P, Jankowski J and Noels H. Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis. Biomedicines. 2022;10.
     
  5. Harlacher E, Wollenhaupt J, Baaten C and Noels H. Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review. Int J Mol Sci. 2022;23.
     
  6. Bhargava S, Merckelbach E, Noels H, Vohra A and Jankowski J. Homeostasis in the Gut Microbiota in Chronic Kidney Disease. Toxins (Basel). 2022;14.
     
  7. Berger M, Baaten C, Noels H, Marx N and Schutt K. [Heart and diabetes : Platelet function and antiplatelet therapy in chronic kidney disease]. Herz. 2022;47:426-433.
     
  8. Baaten C, Schroer JR, Floege J, Marx N, Jankowski J, Berger M and Noels H. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clin J Am Soc Nephrol. 2022;17:155-170.
     
  9. Baaten C, Rigatto C and Noels H. CKD Effects on Platelets: Implications for Cardiovascular Risk. Kidney Int Rep. 2022;7:2126-2128.

 


Stand: Feb 2023

  1. Soppert J, Frisch J, Wirth J, Hemmers C, Boor P, Kramann R, Vondenhoff S, Moellmann J, Lehrke M, Hohl M, van der Vorst EPC, Werner C, Speer T, Maack C, Marx N, Jankowski J, Roma LP and Noels H. A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int. 2021.
     
  2. Orth-Alampour S, Gayrard N, Salem S, Bhargava S, Jankowski V, Jover B, Notarnicola C, Noels H, van der Vorst EPC, Kuppe C, Wolf M, Goettsch C, Theelen W, Bruck H, Fliser D, Loscalzo J, Wu Z, Marx N, Zidek W, Argiles A and Jankowski J. Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation. Basic Res Cardiol. 2021;116:57.
     
  3. Noels H, Lehrke M, Vanholder R and Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17:528-542.
     
  4. Baaten C, Sternkopf M, Henning T, Marx N, Jankowski J and Noels H. Platelet Function in CKD: A Systematic Review and Meta-Analysis. J Am Soc Nephrol. 2021.
     
  5. Baaten C, Schroer J, Floege J, Marx N, Jankowski J, Berger M and Noels H. Platelet Abnormalities in Chronic Kidney Disease and Their Implications for Antiplatelet Therapy. Clin J Am Soc Nephrol. 2021.
  1. Tilstam PV, Soppert J, Hemmers C, Harlacher E, Doring Y, van der Vorst EPC, Schulte C, Alampour-Rajabi S, Theelen W, Asare Y, de Winther MPJ, Lawrence T, Bernhagen J, Schober A, Zernecke A, Jankowski J, Weber C and Noels H. Non-activatable mutant of inhibitor of kappa B kinase alpha (IKKalpha) exerts vascular site-specific effects on atherosclerosis in Apoe-deficient mice. Atherosclerosis. 2020;292:23-30.
     
  2. Sternkopf M, Nagy M, Baaten C, Kuijpers MJE, Tullemans BME, Wirth J, Theelen W, Mastenbroek TG, Lehrke M, Winnerling B, Baerts L, Marx N, De Meester I, Doring Y, Cosemans J, Daiber A, Steven S, Jankowski J, Heemskerk JWM and Noels H. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. Arterioscler Thromb Vasc Biol. 2020;40:e65-e77.
     
  3. Soppert J, Lehrke M, Marx N, Jankowski J and Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020;159:4-33.
     
  4. Noels H and Jankowski J. Editorial on the Special Issue "Comorbidities in Chronic Kidney Disease". Toxins(Basel). 2020;12.
     
  5. Lammers T and Noels H. Lipids in disease pathology, diagnosis & therapy. Adv Drug Deliv Rev. 2020;159:1-3.
     
  6. Holmar J, Noels H, Bohm M, Bhargava S, Jankowski J and Orth-Alampour S. Development, establishment and validation of in vitro and ex vivo assays of vascular calcification. Biochem Biophys Res Commun. 2020;530:462-470.
     
  7. Holmar J, de la Puente-Secades S, Floege J, Noels H, Jankowski J and Orth-Alampour S. Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review. Cells. 2020;9.
     
  8. Hermann J, Noels H, Theelen W, Lellig M, Orth-Alampour S, Boor P, Jankowski V and Jankowski J. Sample preparation of formalin-fixed paraffin-embedded tissue sections for MALDI-mass spectrometry imaging. Anal Bioanal Chem. 2020;412:1263-1275.
     
  9. Doring Y, Noels H, van der Vorst E and Weber C. Seeing is repairing: how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. Eur Heart J. 2020;41:3576-3578.
  1. van der Vorst, E. P. C., Mandl, M., Muller, M., Neideck, C., Jansen, Y., Hristov, M., Gencer, S., Peters, L. J. F., Meiler, S., Feld, M., Geiselhoringer, A. L., de Jong, R. J., Ohnmacht, C., Noels, H., Soehnlein, O., Drechsler, M., Weber, C. & Doring, Y. Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions-Brief Report. Arterioscler Thromb Vasc Biol 39, 685-693, doi:10.1161/ATVBAHA.119.312386 (2019).
     
  2. Sternkopf, M., Thoroe-Boveleth, S., Beck, T., Oleschko, K., Erlenkotter, A., Tschulena, U., Steppan, S., Speer, T., Goettsch, C., Jankowski, V., Jankowski, J., Noels, H. & European Uremic Toxin Work Group, E. A Bifunctional Adsorber Particle for the Removal of Hydrophobic Uremic Toxins from Whole Blood of Renal Failure Patients. Toxins (Basel) 11, doi:10.3390/toxins11070389 (2019).
     
  3. Schick, D., Babendreyer, A., Wozniak, J., Awan, T., Noels, H., Liehn, E., Bartsch, J. W., Vlacil, A. K., Grote, K., Zayat, R., Goetzenich, A., Ludwig, A. & Dreymueller, D. Elevated expression of the metalloproteinase ADAM8 associates with vascular diseases in mice and humans. Atherosclerosis 286, 163-171, doi:10.1016/j.atherosclerosis.2019.03.008 (2019).
     
  4. Noels, H., Weber, C. & Koenen, R. R. Chemokines as Therapeutic Targets in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 39, 583-592, doi:10.1161/ATVBAHA.118.312037 (2019).
     
  5. Gajjala, P. R., Bruck, H., Noels, H., Heinze, G., Ceccarelli, F., Kribben, A., Saez-Rodriguez, J., Marx, N., Zidek, W., Jankowski, J. & Jankowski, V. Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. J Mol Med (Berl) 97, 1451-1463, doi:10.1007/s00109-019-01823-8 (2019).